Immunotherapy for platinum-resistant ovarian cancer.

Giorgio Bogani, Salvatore Lopez, Mara Mantiero, Monika Ducceschi, Sara Bosio, Simona Ruisi, Giuseppe Sarpietro, Rocco Guerrisi, Claudia Brusadelli, Andrea Dell'Acqua, Violante Di Donato, Francesco Raspagliesi

Research output: Contribution to journalArticlepeer-review


Ovarian cancer is characterized by a high mortality on incidence ratio. Although the majority of patients achieve complete response after primary treatment, approximately 65-80 years. Platinum-free interval is one of the main prognostic factors. Patients recurring with 6 months within the end of platinum-based chemotherapy are characterized by poor prognosis. To date no effective treatment modality are identified for those patients. The mainstay of treatment for platinum-resistant ovarian cancer is single agent chemotherapy. Other treatment modalities have tested in this setting with discouraging results. Growing evidence suggested that immunotherapy would improve outcomes of patients with various types of solid tumors including melanoma, non-small cell lung cancer as well as uterine malignancies. Here, we reviewed current evidence on the adoption of immunotherapy in platinum-resistant ovarian cancer. To date no mature evidence supports the routine adoption of immunotherapy in ovarian cancer patients. Further strategies have to be explored.
Original languageEnglish
JournalGynecologic Oncology
Issue number2
Publication statusPublished - Aug 1 2020


Dive into the research topics of 'Immunotherapy for platinum-resistant ovarian cancer.'. Together they form a unique fingerprint.

Cite this